

MARIE CURIE ACTIONS
(MSCF-CT-2006-046108)

Translational Research in Paediatric Rheumatology (TRiPR)

FOURTH CONFERENCE

Biological Agents and Emerging Treatments in the Management of Rheumatic Diseases

May 27th – 30th, 2010
Villa Quartara
Genoa, Italy

Conference Chair

Alberto Martini (Genoa)

Scientific Committee

Abul K. Abbas (San Francisco)

Salvatore Albani (La Jolla)

Ornella Della Casa Alberighi (Genoa)

Marco Gattorno (Genoa)

Wietse Kuis (Utrecht)

Tore K. Kvien (Oslo)

Pierre Miossec (Lyon)

Angelo Ravelli (Genoa)

Nicola Ruperto (Genoa)

Costantino Pitzalis (London)

Provisional Programme



Giannina Gaslini
Institute



International School
of Pediatric Science



University of
Genoa



PRINTO
Pediatric
Rheumatology
International Trials
Organisation



PPRS
Paediatric Rheumatology
European Society



www.tripr.sispge.com

The Project

“Translational **R**esearch in **P**aediatric **R**heumatology” - **TRiPR** - is a series of four events financed by the European Union’s Marie Curie Actions programme for the training and mobility of researchers (Project no. MSCF-CT-2006-046108). TRiPR has the overriding goal of acquainting younger generations of European researchers and clinicians with the key issues underpinning the development of new therapeutic strategies for paediatric rheumatic diseases, seeking above all to enhance their translational research skills in the field.

The Event

Over the last decade biological therapies have represented a major advancement in the treatment of rheumatic diseases. Despite this progress, however, several problems remain. At the same time, breakthroughs in basic and applied research are yielding a myriad of new potential targets for therapies.

The final conference in the TRiPR series of events - *Biological Agents and Emerging Treatments in the Management of Rheumatic Diseases* - will address the treatment of both adult and childhood rheumatic diseases with the purpose of reviewing and discussing the progress that has been achieved thus far, the unmet needs that are still faced, and the potential new treatments that the future holds in store. A final session will be devoted to strategies to improve methodologies of translational research on and clinical development in common, as well as rare, forms of rheumatic disorders.

We look forward to welcoming you to Genoa and the Italian Riviera for what promises to be a rewarding meeting.

A handwritten signature in black ink, which appears to read 'Alberto Martini'.

Alberto Martini
Coordinator, TRiPR

Thursday, May 27th

- 8.30 Registration
- 9.45 Welcome and Introduction
Alberto Martini (Genoa)

Session I Assessing drug response in chronic arthritis

Chairs: *Theodore Pincus (New York) and Walter Grassi (Jesi)*

- 10.00 How to define clinical response in RA
Theodore Pincus (New York)
- 10.30 How to define clinical response in JIA
Angelo Ravelli (Genoa)
- 11.00 The value of MRI in RA
Marco Cimmino (Genoa)
- 11.30 The value of MRI in JIA
Clara Malattia (Genoa)
- 12.00 The value of ultrasonography in RA
Walter Grassi (Jesi)
- 12.30 The value of ultrasonography in JIA
Carlo Martinoli (Genoa)
- 13.00 *Lunch break*

Session II Biological agents

Chairs: *Tore K. Kvien (Oslo) and Stefano Bombardieri (Pisa)*

in Juvenile Idiopathic Arthritis

- 14.30 Etanercept: lessons learned
Edward Giannini (Cincinnati)
- 15.00 Other biological agents
Nicola Ruperto (Genoa)
- 15.30 The case of systemic JIA
Alberto Martini (Genoa)
- 16.00 *Coffee break*

in Rheumatoid Arthritis

- 16.30 Anti-TNF registries in adults: lessons learned
Ronald Van Vollenhoven (Stockholm)
- 17.00 Tocilizumab, Abatacept and Rituximab: the added value
Stefano Bombardieri (Pisa)
- 17.30 The unmet needs in RA
Tore K. Kvien (Oslo)

Selected Oral Presentations

- 18.00 Does anti-TNF therapy increase the risk of skin cancer in patients with RA? results from the British Society for Rheumatology Biologics Register
Kimme Hyrich (Manchester)
- 18.15 Clinical control induced by epitope specific therapy in rheumatoid arthritis is associated with effector T cell modulation and induction of a novel regulatory T cell population
Theo van den Broek (La Jolla)
- 18.30 Quantitative scores from a patient history and physical examination to supplement laboratory tests as standardized "scientific" data in usual clinical care of patients with SLE
Isabel Castrejón (Madrid)
- 18.45 Folate pathway genes that predict methotrexate polyglutamate patterns and response in juvenile idiopathic arthritis
Mara Becker (Kansas City)
- 19.00 *Welcome Reception - Villa Quartara*

Friday, May 28th

Session III Present and future therapies

Chairs: *Dimitrios Boumpas (Heraklion) and Dirk Elewaut (Ghent)*

- 9.00 Optimizing glucocorticoid therapy in rheumatic diseases
Maurizio Cutolo (Genoa)
- 9.30 Spondyloarthropathies
Dirk Elewaut (Ghent)
- 10.00 Systemic lupus erythematosus
Dimitrios Boumpas (Heraklion)
- 10.30 Dermatomyositis
Lucy Wedderburn (London)
- 11.00 *Coffee break*
- 11.30 Vasculitis
Loic Guillevin (Paris)
- 12.00 Autoinflammatory diseases
Marco Gattorno (Genoa)
- 12.30 Scleroderma
Oliver Distler (Zurich)
- 13.00 *Lunch break and poster viewing*

Selected Oral Presentations

Chairs: *Oliver Distler (Zurich) and Loic Guillevin (Paris)*

- 15.00 Treg function at the site of autoimmune inflammation
Ellen J Wehrens (Utrecht)
- 15.15 Wegener's granuloma harbors B cells with specificities towards proinflammatory transmembrane proteins
Jan Voswinkel (Paris)
- 15.30 Functional characterization of human MSCs for their potential clinical use in the treatment of autoimmune diseases
Heba Adelrazik (Cairo)
- 15.45 Neutrophil gene expression profile in systemic JIA patients treated with anakinra
Ebun Omoyinmi (London)
- 16.00 Imatinib mesylate prevents fibrosis and induces regression of established fibrosis in scleroderma models
Paulius Venalis (Vilnius)
- 16.15 Netting neutrophils are major inducers of type I IFN production in SLE
Simone Caielli (Dallas)
- 18.00 *Boat Excursion to San Fruttuoso and Portofino with buffet (weather permitting)*

Saturday, May 29th

Session IV Potential new targets for treatment - I

Chairs: *Abul K. Abbas (San Francisco) and Andreas Radbruch (Berlin)*

- 9.00 Dendritic cells
John D. Isaacs (Newcastle)
- 9.30 B cells and plasma cells
Andreas Radbruch (Berlin)
- 10.00 Regulatory T cells and IL-2
Abul K. Abbas (San Francisco)
- 10.30 P2XR antagonists
Elisabetta Traggiai (Genoa)
- 11.00 *Coffee break*
- 11.30 Neuroinflammation: the cholinergic anti-inflammatory pathway
Paul-Peter Tak (Amsterdam)
- 12.00 Genetic manipulation of the inflammatory response
Christian Jorgensen (Montpellier)
- 12.30 Novel new small molecule and biologic targets for chronic inflammatory disease
Harsukh Parmar (Loughborough)
- 13.00 *Lunch break and poster viewing*

Potential new targets for treatment - II

Chairs: Virginia Pascual (Dallas) and Daniel Kastner (Bethesda)

- 14.30 Kinase inhibitors
Kamran Ghoreschi (Bethesda)
- 15.00 Blocking IL-17
Pierre Miossec (Lyon)
- 15.30 Targets in the bone
Georg Schett (Erlangen)
- 16.00 *Coffee break*
- 16.30 Beyond IL-1: new molecular targets in autoinflammatory diseases
Daniel Kastner (Bethesda)
- 17.00 Anti-interferon- γ
Virginia Pascual (Dallas)
- 17.30 Antigen specific therapy
Berent Prakken (Utrecht)
- 20.00 *Conference Dinner - Aquarium of Genoa (Porto Antico)*

Sunday, May 30th

- 9.00 **Keynote Lecture**
Targeting Toll-like receptors
Luke O'Neill (Dublin)

Session V Facilitating translational research and clinical development in small populations

Chairs: Edward Giannini (Cincinnati) and Patricia Woo (London)

- 9.30 Can synovial pathobiology inform treatment in RA?
Costantino Pitzalis (London)
- 10.00 Biomarkers in rheumatic diseases
Dirk Föll (Münster)
- 10.30 Clinical trials in small populations: issues and challenges
Edward Giannini (Cincinnati)
- 11.00 *Coffee break*
- 11.30 The role of pharmacokinetics for clinical development in small populations
Ornella Della Casa Alberighi (Genoa)
- 12.00 Pharmacovigilance in small populations
Taner Vardar (Geneva)
- 12.30 Translational medicine: from regional challenges to global solutions
Salvatore Albani (La Jolla)
- 13.00 Closing remarks and conference wrap-up
Alberto Martini